Angioimmunoblastic T cell lymphoma
Citation, DOI & article data
Angioimmunoblastic T-cell lymphoma (AITL) (previously known as angioimmunoblastic lymphadenopathy with dysproteinemia (AILD)) is a rare, aggressive (fast-growing) form of peripheral T-cell lymphoma. It only accounts for around 1-2% of all non-Hodgkin lymphoma. It is one of the more common subtypes of mature T-cell lymphomas.
It is more common in the elderly.
The clinical spectrum includes:
Treatment and prognosis
Despite advances in treatment regimens for angioimmunoblastic T cell lymphoma, prognosis remains poor with an overall 5-year median survival of 32% 3.
History and etymology
It was initially described in 1974 by Frizzera et al as angioimmunoblastic lymphadenopathy with dysproteinemia (AILD).
- 1. Rodríguez J, Conde E, Gutiérrez A et-al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur. J. Haematol. 2007;78 (4): 290-6. doi:10.1111/j.1600-0609.2007.00815.x - Pubmed citation
- 2. Lee HJ, Im JG, Goo JM et-al. Peripheral T-cell lymphoma: spectrum of imaging findings with clinical and pathologic features. Radiographics. 2003;23 (1): 7-26. doi:10.1148/rg.231025018 - Pubmed citation
- 3. Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood. 129 (9): 1095-1102. doi:10.1182/blood-2016-09-692541 - Pubmed
- 4. Limpert J, Limpert MH, Limpert VD, Limpert. Angioimmunoblastic lymphadenopathy: clinical and radiological features. (1984) Radiology. doi:10.1148/radiology.152.1.6729133 - Pubmed